Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$36.20 -5.3%	$31.44	$16.50 ▼ $43.58	$3.15B	N/A	48,351 shs	17,211 shs
ACLX Arcellx	$69.92 +1.4%	$63.50	$47.86 ▼ $107.37	$3.85B	0.28	607,317 shs	399,401 shs
DYN Dyne Therapeutics	$8.91 +3.1%	$11.38	$6.36 ▼ $47.45	$1.01B	1.08	1.88 million shs	3.20 million shs
MRUS Merus	$55.62 +2.1%	$50.76	$33.19 ▼ $62.98	$3.85B	1	732,623 shs	694,277 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	-5.33%	-13.89%	+14.88%	+86.12%	+3,619,999,900.00%
ACLX Arcellx	+1.36%	+6.67%	+5.94%	+13.82%	+12.00%
DYN Dyne Therapeutics	+3.12%	+8.92%	-38.17%	+13.50%	-78.55%
MRUS Merus	+2.06%	+5.78%	+1.85%	+28.69%	-2.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ACLX Arcellx	2.5654 of 5 stars	3.5	2.0	0.0	0.0	3.3	2.5	0.0
DYN Dyne Therapeutics	3.4043 of 5 stars	4.5	3.0	0.0	0.0	2.4	2.5	0.0
MRUS Merus	1.9337 of 5 stars	3.6	1.0	0.0	0.0	2.0	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.00	Buy	N/A	N/A
ACLX Arcellx	3.07	Buy	$111.23	59.08% Upside
DYN Dyne Therapeutics	3.00	Buy	$41.13	361.56% Upside
MRUS Merus	3.14	Buy	$84.64	52.17% Upside

Current Analyst Ratings Breakdown

Latest DYN, AAPG, MRUS, and ACLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	DYN Dyne Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/26/2025	DYN Dyne Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
6/25/2025	DYN Dyne Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/24/2025	DYN Dyne Therapeutics	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$13.00
6/18/2025	DYN Dyne Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
6/18/2025	DYN Dyne Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$46.00 ➝ $32.00
6/17/2025	ACLX Arcellx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$110.00
6/17/2025	DYN Dyne Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
6/16/2025	ACLX Arcellx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$115.00
6/11/2025	DYN Dyne Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$37.00
6/2/2025	DYN Dyne Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$60.00 ➝ $34.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$134.35M	23.47	N/A	N/A	$0.48 per share	75.42
ACLX Arcellx	$76.81M	50.16	N/A	N/A	$8.41 per share	8.31
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$6.19 per share	N/A
MRUS Merus	$36.13M	106.54	N/A	N/A	$9.46 per share	5.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	-$55.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ACLX Arcellx	-$107.35M	-$2.99	N/A	N/A	N/A	-211.46%	-35.27%	-22.73%	8/14/2025 (Estimated)
DYN Dyne Therapeutics	-$317.42M	-$3.59	N/A	N/A	N/A	N/A	-52.83%	-48.84%	8/11/2025 (Estimated)
MRUS Merus	-$215.33M	-$4.08	N/A	N/A	N/A	-506.73%	-35.99%	-29.83%	7/30/2025 (Estimated)

Latest DYN, AAPG, MRUS, and ACLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	DYN Dyne Therapeutics	-$0.99	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q1 2025	MRUS Merus	-$1.17	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	MRUS Merus	-$1.17	-$1.40	-$0.23	-$1.40	$7.82 million	$26.49 million
5/8/2025	Q1 2025	ACLX Arcellx	-$0.84	-$1.13	-$0.29	-$1.13	$19.51 million	$8.13 million
5/8/2025	Q1 2025	DYN Dyne Therapeutics	-$0.88	-$1.05	-$0.17	-$1.05	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
ACLX Arcellx	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	3.24	1.26	1.26
ACLX Arcellx	N/A	4.93	4.93
DYN Dyne Therapeutics	N/A	20.35	20.35
MRUS Merus	N/A	5.86	5.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
ACLX Arcellx	96.03%
DYN Dyne Therapeutics	96.68%
MRUS Merus	96.14%

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
ACLX Arcellx	8.35%
DYN Dyne Therapeutics	14.14%
MRUS Merus	4.57%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	600	87.12 million	N/A	N/A
ACLX Arcellx	80	55.11 million	50.51 million	Optionable
DYN Dyne Therapeutics	100	113.67 million	90.06 million	Optionable
MRUS Merus	37	69.21 million	66.05 million	Optionable

DYN, AAPG, MRUS, and ACLX Headlines

Recent News About These Companies

TimesSquare Capital Management LLC Buys 12,510 Shares of Merus N.V. (NASDAQ:MRUS)

1 hour ago | marketbeat.com

Cincinnati Children’s, Christ Hospital partner with developer Merus for project in Cold Spring

July 12 at 12:24 PM | nkytribune.comN

Peter B. Silverman Sells 6,695 Shares of Merus N.V. (NASDAQ:MRUS) Stock

July 12 at 6:15 AM | insidertrades.com

Merus (NASDAQ:MRUS) Upgraded by Wall Street Zen to Hold Rating

July 12 at 2:55 AM | marketbeat.com

Merus N.V. (NASDAQ:MRUS) COO Sells $368,225.00 in Stock

July 11, 2025 | marketbeat.com

Merus N.V. (NASDAQ:MRUS) COO Sells $924,275.00 in Stock

July 11, 2025 | marketbeat.com

MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success

July 11, 2025 | zacks.com

Merus, Bicara Present Promising HNSCC Trial Data at ASCO 2025, Advance Towards Phase III

July 9, 2025 | msn.com

KBC Group NV Sells 54,333 Shares of Merus N.V. (NASDAQ:MRUS)

July 8, 2025 | marketbeat.com

Moody Aldrich Partners LLC Has $4.56 Million Holdings in Merus N.V. (NASDAQ:MRUS)

July 4, 2025 | marketbeat.com

Stocks To Watch: Merus Sees RS Rating Rise To 84

July 2, 2025 | msn.com

Merus N.V.: Making Progress

June 29, 2025 | seekingalpha.com

Merus N.V. (MRUS) Latest Stock News & Headlines - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Stocks Showing Rising Market Leadership: Merus Earns 81 RS Rating

June 25, 2025 | msn.com

Merus N.V. (NASDAQ:MRUS) COO Sells $1,793,840.00 in Stock

June 25, 2025 | insidertrades.com

Peter B. Silverman Sells 34,000 Shares of Merus N.V. (NASDAQ:MRUS) Stock

June 24, 2025 | marketbeat.com

Merus N.V. (NASDAQ:MRUS) Given Average Recommendation of "Buy" by Brokerages

June 21, 2025 | marketbeat.com

Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus

June 11, 2025 | seekingalpha.com

Merus’s Strategic Advancements and Promising Trials Justify Buy Rating with $92 Price Target

June 10, 2025 | tipranks.com

Underappreciated Potential of Merus’s Petosemtamab in Colorectal Cancer: Analyst Highlights Future Opportunities and Financial Stability

June 9, 2025 | tipranks.com

Why Merus N.V. (MRUS) Crashed On Wednesday

June 5, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Top Steel Picks for the Coming Infrastructure Boom
By Chris Markoch | June 25, 2025
View Top Steel Picks for the Coming Infrastructure Boom

DYN, AAPG, MRUS, and ACLX Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$36.20 -2.04 (-5.33%)

As of 07/14/2025 04:00 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Arcellx NASDAQ:ACLX

$69.92 +0.94 (+1.36%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$69.91 -0.01 (-0.01%)

As of 07/14/2025 04:27 PM Eastern

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Dyne Therapeutics NASDAQ:DYN

$8.91 +0.27 (+3.13%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$8.97 +0.06 (+0.67%)

As of 07/14/2025 07:09 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Merus NASDAQ:MRUS

$55.62 +1.12 (+2.06%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$55.66 +0.04 (+0.07%)

As of 07/14/2025 04:11 PM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time